bullish
Green Cross (006280 KS): Hope Still Remains for the U.S. Approval of Blood Derivative Injection
348 Views23 Jun 2022 16:45
SUMMARY
- Green Cross (006280 KS) is expected to receive FDA approval for its immune globulin injection, once the agency conducts onsite inspection of its production facility.
- After suffering in 2021, both blood products and vaccine business are back to double-digit growth path in Q1 2022. The company continues to win export orders for both of these.
- Hunter syndrome and hemophilia treatments are the company’s new growth engines. Green Cross has received approval for its hunter syndrome treatment in China and Japan.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Green Cross (006280 KS): Turns Profitable in Q2; All Eyes on the Maiden US Approval of Blood Product16 Aug 2023
- Green Cross (006280 KS): Strengthening Base Business; US Entry Remains Key Catalyst19 Oct 2022
- Green Cross (006280 KS): Hope Still Remains for the U.S. Approval of Blood Derivative Injection23 Jun 2022
- Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback15 Jan 2022
x